ERBB2 and metastatic neoplasm: It is also important to note that HER2 status is usually assessed in primary gastric tumors and that is the result used to guide therapy for recurrent or metastatic disease; however, discordance in HER2 positivity between primary and metastatic tumors developing either synchronously or metachronously could be misleading.